The DUS1L Knockout NCI-H1299 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human NCI-H1299 cell line. This tool provides a loss-of-function model through CRISPR/Cas9-mediated disruption of the DUS1L gene, enabling researchers to study the functional consequences of DUS1L deficiency in a lung cancer context. The polyclonal format ensures a diverse representation of gene-edited cells, suitable for pooled analysis and functional screens.
The host NCI-H1299 cell line is derived from the metastatic lymph node of a patient with lung adenocarcinoma and serves as a well-characterized model of non-small cell lung cancer (NSCLC). These cells exhibit epithelial morphology and retain key genetic features relevant to NSCLC biology, making them a widely used substrate for cancer research, including studies on oncogenic signaling, metastasis, and therapeutic resistance.
DUS1L encodes a member of the dihydrouridine synthase family that catalyzes the NADPH-dependent reduction of uridine to dihydrouridine in the D-loop of specific tRNAs, notably tRNA-Leu and tRNA-Lys. This post-transcriptional modification is essential for maintaining tRNA structural flexibility and optimal codon?Canticodon interactions during translation. DUS1L interacts directly with tRNA substrates and functionally cooperates with other dihydrouridine synthase family members to modulate translation fidelity. Through its control of translation efficiency, DUS1L indirectly regulates the expression of downstream proteins involved in cell growth and proliferation.
In NCI-H1299 lung cancer cells, DUS1L knockout provides a valuable model for dissecting the contributions of tRNA modification to malignant phenotypes. Given that dysregulation of translational control is a hallmark of cancer, the loss of DUS1L may perturb the synthesis of proteins critical for NSCLC cell survival, migration, or invasion. This polyclonal knockout population allows researchers to assess how diminished dihydrouridine levels impact the cellular proteome and cancer cell behavior, potentially revealing novel nodes of vulnerability in lung adenocarcinoma.
This product is ideally suited for a range of biomedical research applications, including lung cancer biology, tRNA modification studies, translational control, and CRISPR-based functional genomics. Researchers can employ the polyclonal cells in quantitative assays such as Western blotting to monitor protein expression changes, RT-qPCR to analyze tRNA maturation, liquid chromatography?Cmass spectrometry (LC-MS) for dihydrouridine quantification, and functional assays measuring cell proliferation, migration, and invasion. For additional details or technical support, please contact Ascent Research.
